Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Shingles shot put to the test in older HIV patients

NCT ID NCT05575830

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how well the Shingrix vaccine protects against shingles in people over 50 living with HIV, compared to healthy adults of the same age and gender. About 225 participants will receive two doses of the vaccine and be monitored for one year. The goal is to see if the vaccine triggers a strong immune response and is safe in this group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Shingrix (recombinant zoster vaccine)
What this could lead to
If successful, this could show that the Shingrix vaccine works well in older adults with HIV, helping prevent shingles in this group.
What could go wrong
This is a phase 4 study, so the vaccine is already approved. The main question is whether it works as well in people with HIV, but immune responses may be weaker, and side effects like injection-site reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 225 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 95 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For PLWH: * Be registered in the SHCS or in the ANRS CO3 Aquitaine Cohort * Age \>50 YOA * Time since cART initiation \> 10 years * Not already vaccinated with RZV * HIV viral load \<50 copies/ml (within 6 months from the last blood sampling) * Informed consent as documented by signature * (France) : Person affiliated with or beneficiary of the French social security scheme For aged/gender-matched controls * Age \>50 YOA * Not already vaccinated with RZV * Informed consent as documented by signature * (France) Not HIV infected * (France) Person affiliated with or beneficiary of the French social security scheme Exclusion Criteria: * Ongoing signs of febrile or non-febrile infection at the time of the first vaccination * Immunosuppression from the following: * Current malignant neoplasm; * primary immunodeficiency; * recent (\<2 years) solid or bone-marrow transplant or any transplant still requiring immunosuppressive therapy * Intake of drugs which suppress the immune system (e.g. glucocorticoids for a long time \[an equivalent dose of prednisolone \>20 mg/day \> 3 months\], monoclonal antibodies, cytostatics, biological products, etc.) within 6 months before screening. * Administration of immunoglobulins or any blood products within 3 months preceding the first dose of vaccine or planned administration during the study period * Having received a vaccine in the last month or is expected to receive a vaccine in the next month * Having received a shingles vaccine within one year * Presented with herpes zoster in the previous year * Contra-indication to RZV * Hospitalized patients * Unable to provide informed consent or inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * Participation in another study with investigational drug within the 30 days preceding and during the present study. * (France) Pregnant or breastfeeding woman * (France) Patient governed by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bern University Hospital (Inselspital)

    Bern, Canton of Bern, 3010, Switzerland

  • CHU de Bordeaux - Hôpital Haut-Lévèque

    Pessac, Gironde, 33604, France

  • Centre Hospitalier Universitaire Vaudoise (CHUV)

    Lausanne, Canton of Vaud, 1011, Switzerland

  • Ente Ospedaliero Cantonale

    Lugano, Canton Ticino, 6900, Switzerland

  • Hôpital Saint-André, CHU de Bordeaux

    Bordeaux, Bordeaux, 33075, France

  • Kantonsspital

    Sankt Gallen, Canton of St. Gallen, 9007, Switzerland

  • SMIT - Service de Maladies Infectieuses et Tropicales Le Tripode -Groupe Hospitalier Pellegrin

    Bordeaux, France, 33000, France

  • University Hospital Basel

    Basel, Basel, 4031, Switzerland

  • University Hospital Zurich

    Zurich, Canton of Zurich, 8091, Switzerland

  • University Hospitals of Geneva

    Geneva, Canton of Geneva, 1205, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.